Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
InhaleRx Limited ( (AU:IRX) ) has issued an update.
InhaleRx Limited is hosting a shareholder town hall webinar on 23 July 2025 to update on its clinical development programs for IRX-211 and IRX-616a. The company is advancing its inhaled therapies for Breakthrough Cancer Pain and Panic Disorder, with significant economic opportunities anticipated through FDA approval and market introduction, addressing critical treatment gaps.
More about InhaleRx Limited
InhaleRx Limited is an Australian clinical-stage drug development company focused on developing rapid onset, inhaled therapies to address unmet medical needs in the pain management and mental health sectors. The company is working on treatments for Breakthrough Cancer Pain and Panic Disorder, aiming for U.S. FDA approval using efficient regulatory pathways.
Average Trading Volume: 325,160
Technical Sentiment Signal: Buy
Current Market Cap: A$8.96M
For an in-depth examination of IRX stock, go to TipRanks’ Overview page.